Open Access
Postoperative survival results of patients with stage I-II malignant pleural mesothelioma in an endemic area
Author(s) -
Tayfun Kermenli̇,
Cebrail Azar
Publication year - 2020
Publication title -
sanamed
Language(s) - English
Resource type - Journals
eISSN - 2217-8171
pISSN - 1452-662X
DOI - 10.24125/sanamed.v15i2.442
Subject(s) - medicine , decortication , surgery , chemotherapy , mesothelioma , stage (stratigraphy) , radiation therapy , paleontology , pathology , biology
Introduction: The accepted treatment option for malignant pleural mesothelioma (MPM) is multimodality treatment including surgery, chemotherapy and radiotherapy. In this study, we aimed to evaluate the results of patients who underwent surgical resection for multimodality treatment due to MPM at our clinic between July 2015 and October 2019. Method: The results of 13 patients who underwent surgical treatment for MPM in our clinic were evaluated retrospectively. Patients' demographic structure, regions where they live, symptom presentation, disease localization, biopsy diagnosis, type of surgical treatment, choice of neoadjuvant or adjuvant chemotherapy, postoperative complications and survival outcomes were evaluated. Results: The mean survival time was 19.6 months. Six patients were still under follow-up. One patient whose postoperative pathology was reported as mixed type had the worst survival with 13 months and the best survival was 32 months in the patient who underwent postoperative hyperthermic chemotherapy with pleural decortication. Four patients died due to local recurrence and general condition disorder, and two patients died after peritonitis carcinomatosis and ascites. Conclusion: Epitheloid type multimodality treatment and intrapleural hyperthermic chemotherapy may be a good choice in patients with the stage I and II malignant mesothelioma without surgical comorbidity